<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Liotrix</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01583</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01583/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01583/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01583.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01583.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01583.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01583.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01583.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01583">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bitiron </td><td>Abdi (Turkey)</td></tr><tr><td>Combithyrex </td><td>Sandoz (Austria)</td></tr><tr><td>Cynoplus</td><td>Grossman (Mexico)</td></tr><tr><td>Dithyron </td><td>Unipharma (Greece)</td></tr><tr><td>Euthroid</td><td>Parke, Davis (United States) (discontinued)</td></tr><tr><td>Euthyral</td><td>Merck-Lipha (France)</td></tr><tr><td>Eutroid</td><td>Elea (Argentina)</td></tr><tr><td>Levotiroxina</td><td>Farmedica (Brazil) (discontinued)</td></tr><tr><td>Levotrin </td><td>GlaxoSmithKline (Argentina)</td></tr><tr><td>Novothyral </td><td>Merck (Austria, Belgium, Chile, Germany, Poland, Russia, Switzerland)</td></tr><tr><td>Novotiral</td><td>Merck (Mexico)</td></tr><tr><td>Prothyrid </td><td>Henning (Germany), Sanofi-Aventis (Germany), Sanofi Synthelabo (Austria) (discontinued)</td></tr><tr><td>Thyrolar</td><td>Forest Pharmaceuticals (United States)</td></tr><tr><td>Tiroide Amsa</td><td>Amsa (Italy)</td></tr><tr><td>Tyroplus</td><td>Enila (Brazil) (discontinued)</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hormone-replacement-agents">Hormone Replacement Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>8065-29-0</td></tr><tr><th>Weight</th><td>Average: 1471.8072<br>Monoisotopic: 1471.440608948</td></tr><tr><th>Chemical Formula</th><td>C<sub>30</sub>H<sub>21</sub>I<sub>7</sub>N<sub>2</sub>Na<sub>2</sub>O<sub>8</sub></td></tr><tr><th>InChI Key</th><td>LKYWLLWWYBVUPP-XOCLESOZSA-L</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">disodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[Na+].[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C([O-])=O.N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy.</td></tr><tr><th>Pharmacodynamics</th><td>Thyroid hormone drugs are natural or synthetic preparations containing T<sub>4</sub> or T<sub>3</sub> or both. T<sub>4</sub> and T<sub>3</sub> are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. Liotrix is a synthetic preparation of T4 and T3 in a 4:1 weight-based ratio. These hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system.</td></tr><tr><th>Mechanism of action</th><td>The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major secreted form of thyroid hormone is T4. T4 is converted T3, the more active thyroid hormone, by deiodinases in peripheral tissues. T3 acts in the body to increase basal metabolic rate, alter protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). Thyroid hormones are essential for proper development and differentiation of all cells of the human body. T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism to varying extents. The most pronounced effect of the hormones is in altering how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Thyroid hormones are primarily eliminated by the kidneys.</td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Hypermetabolic state indistinguishable from thyrotoxicosis of endogenous origin. Symptoms of thyrotoxicosis include weight loss, increased appetite, palpitations, nervousness, diarrhea, abdominal cramps, sweating, tachycardia, increased pulse and blood pressure, cardiac arrhythmias, tremors, insomnia, heat intolerance, fever, and menstrual irregularities.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9265</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.5572</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6254</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5404</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9229</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9089</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8928</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8097</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.878</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7092</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5872</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6523</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8638</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8585</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8711</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8243</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.763
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8526
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9697
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5191 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9672
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8731
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Forest pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Santen inc</li>
<li>Merck co inc</li>
<li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.forestpharm.com">Forest Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>100 mcg/25 mcg</td></tr><tr><td>Tablet</td><td>Oral</td><td>12.5 mcg/3.1 mcg</td></tr><tr><td>Tablet</td><td>Oral</td><td>150 mcg/37.5 mcg</td></tr><tr><td>Tablet</td><td>Oral</td><td>25 mcg/6.25 mcg</td></tr><tr><td>Tablet</td><td>Oral</td><td>50 mcg/12.5 mcg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00258">Calcium Acetate</a></td><td>Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>The resin, cholestyramine, decreases the absorption of the thyroid hormone, liotrix.</td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>The resin, colestipol, decreases the absorption of the thyroid hormone, liotrix.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>The thyroid hormone, liotrix, decreases the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Absorption increased in fasting state and decreased in malabsorption states.</li>
<li>Consistent administration in relation to meals is recommended.</li>
<li>Iron and calcium may interfere with absorption. Space doses at least one hour before or after iron or calcium intake. </li>
<li>Oral administration with infant soybean formula, soybean flour, cotton seed meal, walnuts, foods containing large amounts of fiber, ferrous sulfate, and antacids may decrease drug absorption. </li>
<li>Take 30-60 minutes before breakfast.</li></ul></td></tr></tbody></table>